Precision psychiatry

DDW has published the latest addition to its Guide Series, ‘Unlocking neuroscience drug discovery’. It covers the way the neuroscience sector is overcoming drug discovery challenges, advances in neuroscience and the era of precision neuroscience. Download to find out: Neuroscience drug discovery advances and challenges and how breakthroughs in this field are helping address areas […]

A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD).   In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a significantly greater change in Montgomery-Åsberg Depression Rating Scale […]

The Psychiatry Consortium and the British Neuroscience Association recently published their ‘Guiding Principles for Robust Target Validation in Psychiatry’. Dr Ekta Patel, Psychiatry Consortium Partnership Manager, spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new therapeutic targets in this underfunded specialty.  […]

Mike McCully, CEO of Gate Neurosciences, speaks to DDW’s Diana Spencer about the company’s pipeline of next-generation antidepressants and why this could be the most exciting time in the history of psychiatry. DS: How has our understanding of the brain developed in the last 70 years?  MM: Although our understanding of the brain is still […]